Copper Histidine

Summary

Copper Histidine (CHEMBL4297731) is a phase-3 clinical-stage unknown; indicated across 1 condition including menkes disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297731
Name	Copper Histidine
Type	Unknown
Max phase	3

Also known as: Bishistidine copper(ii) salt, Copper histidinate, Copper histidine, Copper l-histidinate, Copper, bis(l-histidinato)-, Copper, bis(l-histidinato-n,o)-, CUTX-101, J1.412.545K, Zycubo, COPPER HISTIDINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Menkes disease	3	MONDO:0010651	MONDO:0010651

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00811785	PHASE3	COMPLETED	Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
NCT00001262	PHASE1/PHASE2	COMPLETED	Copper Histidine Therapy for Menkes Diseases
NCT04074512	Not specified	APPROVED_FOR_MARKETING	Copper Histidinate Treatment for Menkes Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).